PE20050415A1 - Acidos carboxilicos alfa sustituidos como moduladores ppar - Google Patents
Acidos carboxilicos alfa sustituidos como moduladores pparInfo
- Publication number
- PE20050415A1 PE20050415A1 PE2004000361A PE2004000361A PE20050415A1 PE 20050415 A1 PE20050415 A1 PE 20050415A1 PE 2004000361 A PE2004000361 A PE 2004000361A PE 2004000361 A PE2004000361 A PE 2004000361A PE 20050415 A1 PE20050415 A1 PE 20050415A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- alkyl
- oxazol
- phenyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS ACIDOS CARBOXILICOS ALFA SUSTITUIDOS DE FORMULA (I), DONDE Q ES ARILO(C6-C10) O HETEROCICLILO DE 4 A 10 ESLABONES; R1 ES H, HALO, ALQUILO(C1-C8), ALCOXI(C1-C8), CN, CF3, -O-CF3-, -O-SO2-ALQUILO(C1-C8), ENTRE OTROS; R2 ES H, ALQUILO(C1-C8), -(CR11R12)t-CICLOALQUILO(C3-C10), ENTRE OTROS DONDE LOS ATOMOS DE C ESTAN OPCIONALMENTE SUSTITUIDOS CON 1 A 3 GRUPOS R13 Y LOS ATOMOS DE N DE R2 PUEDEN ESTAR SUSTITUIDOS POR ALQUILO(C1-C8); R3 ES -R4-Ar1-Ar2-R5-C(R6R7)-R8, -R4-Y-Y"-(C)p(R11R12)-Ar3-R5-C(R6R7R8), ENTRE OTROS, DONDE CADA Ar ES ARILO(C6-C10) O HETEROCICLILO(C5-C10) ESLABONES OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: ACIDO 1-({3´-[2-(5-METIL-2-FENIL-1,3-OXAZOL-4-IL)ETOXI]-1,1´-BIFENIL-3-IL}OXI)CICLOBUTANOCARBOXILICO, ACIDO 2-METIL-2-{3-[({[2-(5-METIL-2-FENIL-1,3-OXAZOL-4-IL)ETOXI]CARBONIL}AMINO)METIL]FENOXI}PROPANOICO, ACIDO 2-ETOXI-3-{6-{2-(5-METIL-2-FENIL-1,3-OXAZOL-4-IL)ETOXI]PIRIDIN-3-IL}PROPANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS MODULAN LA ACTIVIDAD DEL RECEPTOR ACTIVADO-PROLIFERADOR DE PEROXISOMAS (PPAR) Y SON UTILES PARA MODULAR LA GLUCOSA EN SANGRE E INCREMENTAR LA SENSIBILIDAD A INSULINA, PARA EL TRATAMIENTO DE DIABETES, DISLIPIDEMIA OBESIDAD Y TRANSTORNOS INFLAMATORIOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46321303P | 2003-04-15 | 2003-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050415A1 true PE20050415A1 (es) | 2005-06-13 |
Family
ID=33300053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000361A PE20050415A1 (es) | 2003-04-15 | 2004-04-12 | Acidos carboxilicos alfa sustituidos como moduladores ppar |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1615899A1 (es) |
JP (1) | JP2006523671A (es) |
KR (1) | KR20060009846A (es) |
CN (1) | CN1805943A (es) |
AP (1) | AP2005003418A0 (es) |
AR (1) | AR044514A1 (es) |
AU (1) | AU2004230316A1 (es) |
BR (1) | BRPI0409429A (es) |
CA (1) | CA2521915A1 (es) |
CL (1) | CL2004000800A1 (es) |
EA (1) | EA200501462A1 (es) |
EC (1) | ECSP056105A (es) |
IS (1) | IS8033A (es) |
MA (1) | MA27764A1 (es) |
MX (1) | MXPA05010967A (es) |
NL (1) | NL1025946C2 (es) |
NO (1) | NO20055370L (es) |
OA (1) | OA13157A (es) |
PA (1) | PA8600201A1 (es) |
PE (1) | PE20050415A1 (es) |
TN (1) | TNSN05262A1 (es) |
TW (1) | TW200510353A (es) |
UY (1) | UY28266A1 (es) |
WO (1) | WO2004092145A1 (es) |
ZA (1) | ZA200508362B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200610650B (en) * | 2004-05-25 | 2009-04-29 | Metabolex Inc | Substituted triazoles as modulators of PPAR and methods of their preparation |
AP2358A (en) | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
US8962825B2 (en) | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
BRPI0808495A2 (pt) | 2007-03-08 | 2014-07-22 | Albireo Ab | Derivados de ácido 2-substituído-3-fenilpropiônico e seu uso no tratamento de doença inflamatória intestinal |
CA2687817A1 (en) | 2007-05-22 | 2008-12-04 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
CA2728228A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
CA2729909A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
BRPI0916713A2 (pt) | 2008-07-28 | 2015-11-10 | Gilead Science Inc | compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno |
KR20120024722A (ko) | 2009-06-08 | 2012-03-14 | 길리애드 사이언시즈, 인코포레이티드 | 시클로알킬카르바메이트 벤즈아미드 아닐린 hdac 저해제 화합물 |
CA2763786C (en) | 2009-06-08 | 2014-09-30 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
DE102010055499A1 (de) * | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
FR2982858B1 (fr) * | 2011-11-18 | 2013-11-29 | Rhodia Operations | Procede de fabrication de composes comprenant des fonctions nitriles |
FR2984322B1 (fr) * | 2011-12-16 | 2013-12-20 | Rhodia Operations | Procede de fabrication de composes comprenant des fonctions nitriles |
IN2014MN02574A (es) | 2012-05-22 | 2015-07-24 | Genentech Inc | |
US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
MX2016006936A (es) | 2013-11-27 | 2016-10-05 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas. |
CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
JP2018520107A (ja) | 2015-05-22 | 2018-07-26 | ジェネンテック, インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
MX2018003828A (es) | 2015-09-28 | 2018-06-22 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso. |
CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
JP2019532077A (ja) | 2016-10-17 | 2019-11-07 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60007592T2 (de) * | 1999-09-30 | 2004-09-16 | Pfizer Products Inc., Groton | Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren |
JP2004520397A (ja) * | 2001-02-15 | 2004-07-08 | ファイザー・プロダクツ・インク | 増殖性アクチベータ受容体(ppar)化合物 |
-
2004
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/pt not_active IP Right Cessation
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/es not_active Application Discontinuation
- 2004-04-01 EA EA200501462A patent/EA200501462A1/ru unknown
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/ko not_active Application Discontinuation
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/zh active Pending
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Application Discontinuation
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/xx unknown
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/ja active Pending
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/es not_active Application Discontinuation
- 2004-04-13 UY UY28266A patent/UY28266A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/es unknown
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/es unknown
- 2004-04-14 TW TW093110410A patent/TW200510353A/zh unknown
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/es unknown
- 2004-04-14 NL NL1025946A patent/NL1025946C2/nl not_active IP Right Cessation
-
2005
- 2005-09-15 IS IS8033A patent/IS8033A/is unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/fr unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/fr unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/es unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY28266A1 (es) | 2004-11-30 |
NL1025946C2 (nl) | 2005-02-01 |
AU2004230316A1 (en) | 2004-10-28 |
TNSN05262A1 (fr) | 2007-07-10 |
OA13157A (en) | 2006-12-13 |
KR20060009846A (ko) | 2006-02-01 |
BRPI0409429A (pt) | 2006-04-18 |
TW200510353A (en) | 2005-03-16 |
NL1025946A1 (nl) | 2004-10-18 |
NO20055370D0 (no) | 2005-11-14 |
MXPA05010967A (es) | 2005-11-28 |
PA8600201A1 (es) | 2005-02-04 |
CL2004000800A1 (es) | 2005-03-04 |
EA200501462A1 (ru) | 2006-04-28 |
AR044514A1 (es) | 2005-09-14 |
EP1615899A1 (en) | 2006-01-18 |
ECSP056105A (es) | 2006-03-01 |
WO2004092145A1 (en) | 2004-10-28 |
WO2004092145A8 (en) | 2005-05-12 |
IS8033A (is) | 2005-09-15 |
CN1805943A (zh) | 2006-07-19 |
ZA200508362B (en) | 2006-11-29 |
JP2006523671A (ja) | 2006-10-19 |
CA2521915A1 (en) | 2004-10-28 |
AP2005003418A0 (en) | 2005-12-31 |
NO20055370L (no) | 2006-01-12 |
MA27764A1 (fr) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050415A1 (es) | Acidos carboxilicos alfa sustituidos como moduladores ppar | |
DE60222006T2 (de) | Heterozyklische verbindungen und ihre verwendungen | |
DE60315603T2 (de) | Modulatoren von peroxisome proliferator-aktivierten rezeptoren | |
JP4583760B2 (ja) | 疼痛の治療に有用な治療薬 | |
JP6336561B2 (ja) | Ii型糖尿病を処置するためのgpr120アゴニスト | |
NO20074324L (no) | Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer | |
JP5400030B2 (ja) | ジペプチジルペプチダーゼivの阻害剤としてのn−置換チオモルホリン誘導体およびその医薬的使用 | |
TWI691475B (zh) | Urat1抑制劑 | |
PE20080069A1 (es) | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) | |
PE20081485A1 (es) | Derivados de sulfonamida | |
JP2009280595A5 (es) | ||
BRPI0706790A2 (pt) | composto de amina trissubstituìda | |
PE20081059A1 (es) | Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) | |
ATE440091T1 (de) | Antidiabetische bicyclische verbindungen | |
KR20120114355A (ko) | 화합물 및 방법 | |
FR2890072A1 (fr) | Nouveaux composesde pyrrolopyridine | |
PE20090999A1 (es) | Nuevos derivados de metil-bencimidazol | |
CN103547570A (zh) | 可用作胰高血糖素受体拮抗剂的吡啶甲酰胺基-丙酸衍生物 | |
PE20090652A1 (es) | Compuestos de nicotinamida sustituida y sus usos en medicamentos | |
PE20110773A1 (es) | Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion | |
Seto et al. | Design, Synthesis, and Structure− Activity Relationship Studies of Novel 2, 4, 6-Trisubstituted-5-pyrimidinecarboxylic Acids as Peroxisome Proliferator-Activated Receptor γ (PPARγ) Partial Agonists with Comparable Antidiabetic Efficacy to Rosiglitazone | |
PE20040580A1 (es) | Moduladores de receptor activado de proliferador de peroxisoma con engarce amida | |
Tanaka et al. | Discovery of novel N-phenylglycine derivatives as potent and selective β3-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence | |
JP6303031B2 (ja) | Ii型糖尿病を処置するためのgpr120アゴニストとしてのイソチアゾール誘導体 | |
CN103153990B (zh) | 新型吡啶基苯并噁嗪衍生物、包含其的药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |